AST-2818
- Generic Name
- AST-2818
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Phase 3
Recruiting
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)EGFR
- Interventions
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06956001
- Locations
- 🇨🇳
Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences, BeiJing, Beijing, China
🇨🇳Shandong Tumor Hospital, Shandong, Jinan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath